Table 1.

Patents Characteristics

Cohort (Dose-Level)	Pt #	Sex/ Age, y	Diagnosis-status at alloHSCT	Disease Risk	Donor type	Conditioning Regimen	Days from alloHSCT to Dec	Chimerism at enrollment, %
1 (5 mg/m2)	1	M/62	AML-PD	Ph+ AML	mMUD	BU/CY	95	100
	2	F/59	AML-PD	Prior MF, trisomy 8, FLT3-ITD +	MRD	BU/CY	62	Mixed
	3	M/37	AML-CR1	Monosomy 7	MUD	BU/CY	75	100
	4	M/62	AML-PD	Prior MDS, trisomy 19	MUD	TBI/CY	95	Mixed
	5	M/57	MDS	Trisomy 8, 5q-	MUD	BU/CY	76	100
	6	M/59	AML-CR2	t (8,21), CR2	MUD	BU/CY	77	100
	7	M/42	AML-CR1	Del 12/ETV6	mMUD	BU/CY	115	100
	8	M/52	MDS	Del 5, Del 6	MUD	BU/CY	90	100
	9	M/58	AML-CR1	Complex cytogenetics	MRD	BU/CY	98	100
2 (7.5 mg/m2)	10	F/68	AML-CR1	Complex cytogenetics	MRD	FLU/BU	96	100
	11	F/65	AML-CR1	FLT 3-ITD +	MUD	TBI/CY	96	100
	12	F/45	AML-CR1	Therapy related AML	mMRD	BU/CY	98	100
	13	M/63	AML-CR1	Prior MDS	mMUD	BU/CY	103	100
3 (10 mg/m2)	14	M/21	AML-CR1	FLT3-ITD +	MUD	BU/CY	97	100
	15	F/56	AML-CR1	Complex cytogenetics	MUD	BU/CY	87	100
	16	M/62	MDS	High-grade MDS	MUD	BU/CY	95	100
	17	M/63	AML-CR1	Prior MDS	MRD	BU/CY	102	100
4 (15 mg/m2)	18	F/54	AML-CR2	CR2	MRD	BU/CY	95	100
	19	F/51	AML-CR1	MLL rearrangement	MUD	BU/CY	82	100
	20	M/57	MDS	Del 7	mMUD	BU/CY	86	100
	21	M/67	AML-CR1	Del 17p (p53)	MUD	FLU/BU	74	100
	22	M/66	MDS	High-grade MDS	MRD	BU/CY	100	100

AlloHSCT indicates allogeneic hematopoietic stem cell transplantation; AML, acute myelogenous leukemia; BU, busulfan; CR, complete remission; CY, cyclophosphamide; Dec, decitabine; Del, deletion; Flu, fludarabine; GVHD, graft-versus-host disease; MDS, melodysplastic syndrome; MF, myelofibrosis; mMRD, mismatched related donor; mMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; PD, persistent disease; Ph, Philadelphia chromosome; Pt, patient; TBI, total body irradiation.